PolyPid PYPD 深 滬
等待開盤 07-18 09:30:00 美东时间
3.80
+0.030
+0.80%
華盛通- 最 高3.87
- 今 開3.78
- 成交量 18.22万股
- 最 低 3.72
- 昨 收 3.77
- 總市值 3872.54万
- 52周最高 4.42
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 2.30
- 委 比 -66.67%
- 總股本 1019.09万
- 歷史最高 583.50
- 量 比 0.96
- 振 幅 3.98%
- 歷史最低 2.30
- 每 手 1
- 風險率 0.35%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market
PolyPid Ltd. has unveiled a long-acting GLP-1 receptor agonist delivery platform that aims to subcutaneously release GLP-1 RA for approximately 60 days, significantly longer than current weekly injection regimens. This technology, which releases GLP-1 in a linear manner, seeks to improve medication adherence and patient outcomes in diabetes and obesity treatment. The platform expands PolyPid's product portfolio beyond its recent Phase 3 success w...
07-15 12:00
美股大行评级 | 潜在涨幅261.01%！瑞穗上调Immuneering目标价至10美元，维持"跑赢大市"评级
康托·菲茨杰拉德：维持Meta Platforms(META)"超配"评级，目标价从676美元升至807美元
06-19 09:23
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
06-18 09:46
PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results
PolyPid Ltd. has secured $26.7 million in additional funding through the exercise of warrants, extending its runway beyond FDA approval of D-PLEX₁₀₀. D-PLEX₁₀₀ demonstrated significant reduction in surgical site infections in Phase 3 SHIELD II trial, meeting primary and secondary endpoints. The funds will support FDA application, launch preparations, and general operations. The Company issued new warrants exercisable at $4.50 per share, with proc...
06-16 23:20
美股大行评级 | eToro Group获多家大行首予买入评级，甲骨文获多家机构上调目标价
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1139116149842006017.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持PolyPid(PYPD)"买入"评级，目标价从11美元升至13美元</p> <p>• HC Wainwright & Co.：维持Vertical Aerosp
06-10 09:45
PolyPid's Surgery Drug Cuts Infection Risk by 38% in Major Phase 3 Trial
PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced positive topline results from its pivotal SHIELD II Phase 3 trial of
06-09 19:33
PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints
PolyPid Ltd. announced positive results from its SHIELD II Phase 3 trial of D-PLEX 100 for preventing surgical site infections (SSIs) in abdominal colorectal surgery. The trial met its primary efficacy endpoint, showing a 38% reduction in SSIs, mortality, and surgical reinterventions (p<0.005). Secondary endpoints were also met, with a 58% reduction in SSI rates (p<0.005) and a 62% reduction in ASEPSIS scores (p<0.05). D-PLEX 100 is expected to s...
06-09 11:30
美股大行评级 | 潜在涨幅925.64%！Aemetis获Ascendiant Capital升目标价至20美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1138028221594226688.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Ascendiant Capital：维持Aemetis(AMTX)"买入"评级，目标价从19美元升至20美元</p> <p>• Ascendiant Capital：维持Lucid Diagnostics(LUCD)"买
06-07 08:37
PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
PolyPid Ltd. will host a conference call and webcast on June 9, 2025, at 8:30 a.m. ET, to discuss topline data from the SHIELD II Phase 3 trial for D-PLEX100, aimed at preventing surgical site infections in abdominal colorectal surgery. The trial is evaluating the effectiveness of the company's lead product candidate. For meeting details and registration, visit the provided links. PolyPid, a late-stage biopharma company, uses its PLEX technology ...
06-06 20:05
美股大行评级 | 潜在涨幅6326.33%！Ascendiant Capital上调Plus Therapeutics目标价至20.5美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1137665801621229569.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Ascendiant Capital：维持Plus Therapeutics(PSTV)"买入"评级，目标价从20美元升至20.5美元</p> <p>• Ascendiant Capital：维持RenovoRx(RNXT
06-06 09:45
